Π

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

to

FORM 4

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average burden										
hours per response:	0.5									

1. Name and Addres <u>GOLDBERG</u>	s of Reporting Persor MORTON	* 	2. Issuer Name and Ticker or Trading Symbol <u>EYEGATE PHARMACEUTICALS INC</u> [EYEG]		tionship of Reporting Persol all applicable) Director Officer (give title	n(s) to Issuer 10% Owner Other (specify	
	(First) PHARMACEUTI(7 OAKS ROAD, S	Č.	3. Date of Earliest Transaction (Month/Day/Year) 06/03/2016		below)	below)	
(Street) WALTHAM (City)	MA (State)	02452 (Zip)	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line) X	idual or Joint/Group Filing (Form filed by One Report Form filed by More than C Person	ing Person	

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

······································											
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Execution Date, Transaction Disposed				5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership			
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)	
Common Stock	06/03/2016		М		33,775	A	\$0.6478	43,216	D		
Common Stock	06/03/2016		S		4,650	D	\$3.3743(1)	38,566	D		
Common Stock	06/06/2016		S		5,543	D	\$3.2546(2)	33,023	D		
Common Stock	06/07/2016		S		746	D	\$3.3144 ⁽³⁾	32,277	D		

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

	(e.g., puts, calls, warrants, options, convertible securities)														
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (right to buy)	\$ 0.6478	06/03/2016		М			14,493	(4)	09/29/2018	Common Stock	14,493	\$0	0	D	
Stock Option (right to buy)	\$ 0.6478	06/03/2016		М			5,353	(4)	01/29/2020	Common Stock	5,353	\$0	0	D	
Stock Option (right to buy)	\$ 0.6478	06/03/2016		М			2,276	(4)	01/29/2020	Common Stock	2,276	\$0	0	D	
Stock Option (right to buy)	\$ 0.6478	06/03/2016		М			3,809	(4)	06/25/2020	Common Stock	3,809	\$0	0	D	
Stock Option (right to buy)	\$ 0.6478	06/03/2016		М			5,112	(4)	01/14/2021	Common Stock	5,112	\$0	0	D	
Stock Option (right to buy)	\$ 0.6478	06/03/2016		М			2,732	(5)	12/23/2022	Common Stock	2,732	\$0	0	D	

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$3.30 to \$3.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$3.21 to \$3.35, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$3.30 to \$3.36, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.

4. The Reporting Person was granted options to purchase these shares pursuant to the Issuer's 2005 Equity Incentive Plan. Each option become exercisable immediately upon grant.

5. The Reporting Person was granted an option to purchase these shares pursuant to the Issuer's 2005 Equity Incentive Plan. The option became exercisable as to 33% of the shares underlying the option on December 23, 2013, with 2.79% of the shares underlying the option vesting monthly thereafter.

<u>/s/ J. Fraser Collin, attorney-in-</u> <u>fact*</u> 06/07/2016

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.